Biomea Fusion

Biomea Fusion is a diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.